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Abstract: To ameliorate diabetes mellitus-associated heart failure with preserved ejection fraction
(HFpEF), we plan to lower diabetes-mediated oxidative stress-induced 4-hydroxy-2-nonenal (4HNE)
accumulation by pharmacological agents that either decrease 4HNE generation or increase its detoxification.A cellular reactive carbonyl species (RCS), 4HNE, was significantly increased in diabetic hearts
due to a diabetes-induced decrease in 4HNE detoxification by aldehyde dehydrogenase (ALDH) 2, a
cardiac mitochondrial enzyme that metabolizes 4HNE. Therefore, hyperglycemia-induced 4HNE is
critical for diabetes-mediated cardiotoxicity and we hypothesize that lowering 4HNE ameliorates
diabetes-associated HFpEF. We fed a high-fat diet to ALDH2*2 mice, which have intrinsically low
ALDH2 activity, to induce type-2 diabetes. After 4 months of diabetes, the mice exhibited features of
HFpEF along with increased 4HNE adducts, and we treated them with vehicle, empagliflozin (EMP)
(3 mg/kg/d) to reduce 4HNE and Alda-1 (10 mg/kg/d), and ALDH2 activator to enhance ALDH2
activity as well as a combination of EMP + Alda-1 (E + A), via subcutaneous osmotic pumps. After
2 months of treatments, cardiac function was assessed by conscious echocardiography before and
after exercise stress. EMP + Alda-1 improved exercise tolerance, diastolic and systolic function, 4HNE
detoxification and cardiac liver kinase B1 (LKB1)-AMP-activated protein kinase (AMPK) pathways in
ALDH2*2 mice with diabetes-associated HFpEF. This combination was even more effective than EMP
alone. Our data indicate that ALDH2 activation along with the treatment of hypoglycemic agents
may be a salient strategy to alleviate diabetes-associated HFpEF.
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Multiple factors contribute to heart failure with preserved ejection fraction (HFpEF), a
condition that remains poorly understood and difficult to study or treat. The protean nature
of HFpEF makes it unsurprising that there is not a single animal model that can mimic all
the characteristics of HFpEF [1]. This can be cleverly segregated into individual models of
HFpEF based on their etiopathophysiology, such as models of atrial fibrillation-mediated
HFpEF, pulmonary hypertension-mediated HFpEF and diabetes-mediated HFpEF [1]. In
this study, our focus will be on HFpEF associated with type-2 diabetes mellitus (type 2 DM).
Among various factors in diabetes, hyperglycemia-mediated oxidative stress has been
regarded as critical for end-organ damage via multiple pathways [2,3]. Oxidative stress
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is a complex and continuous process. Reactive oxygen species (ROS) generation is the
initiating event of oxidative stress. Although ROS have a short half-life, they produce 4hydroxy-2-nonenal (4HNE) similar to reactive carbonyls by lipid peroxidation. In addition,
4HNE is known to form adducts with proteins, DNA and extracellular matrix, and we
have shown increased 4HNE adducts in both type-1 and type-2 diabetic hearts compared
to controls [4–6], which contribute to cardiac damage and dysfunction [7]. In myocardial
cells, 4HNE is detoxified by glutathione, aldehyde dehydrogenases (ALDHs) and aldose
reductase [8]. We showed a significant increase in 4HNE adducts in cultured cardiac
cells [9–12] and cardiac tissue [4–6,13], which is augmented by reduced ALDH2 activity by
employing either diabetic insult or pharmacological inhibition or genetic mutation.
A single point E487K mutation in ALDH2 (prevalent in East Asians) known as
ALDH2*2 reduces its activity to ~3% in homozygotes (ALDH2*2/2) and ~30–50% in
heterozygotes (ALDH2*2/1). We employed ALDH2*2 knock-in heterozygous mutant mice,
which mimic East Asians with the ALDH2*2 mutation that have intrinsically low ALDH2
activity. In fact, a recent clinical study in East Asians with the ALDH2*2 mutation demonstrated an association between ALDH2*2 and HFpEF in patients who have diabetes and
other comorbidities [14]. Even before this study, we were the first group to demonstrate
that ALDH2*2 mutant mice with type-2 DM exhibited an exacerbation of HFpEF features
relative to wild-type mice with type-2 DM [6].
In this study, we plan to only use pharmacological approaches as the majority of
current therapeutic management is still implemented through drugs. In our earlier study,
we decreased cardiac 4HNE adduct levels in ALDH2*2 diabetic mice by decreasing hyperglycemia via empagliflozin (EMP), a sodium-glucose cotransporter (SGLT) 2 inhibitor, and
thereby improved cardiac function via altering metabolic signaling [15]. Therefore, in addition to decreasing 4HNE generation via EMP, we also want to increase 4HNE detoxification
via ALDH2 activation by Alda-1, a small molecule ALDH2 activator. Alda-1 was first
shown to increase both wild-type (WT) ALDH2 and ALDH2*2 activity and decrease 4HNE
adductions in vitro and in the myocardium of rats subjected to ischemia-reperfusion [16].
Therefore, in this study, we will test the hypothesis that combining both lowering
cardiac 4HNE adducts by reducing hyperglycemia-mediated oxidative stress and increasing
4HNE detoxification by ALDH2 activation should ameliorate DM-associated HFpEF in
ALDH2*2 mice.
2. Results
2.1. Effects of EMP, Alda-1 and EMP + Alda-1 on HFD-Induced Body Weight (BW) Gain and
Type-2 Diabetes-Mediated Hyperglycemia
HFD feeding increased body weight gain in ALDH2*2 mice compared to chow fed
ALDH2*2 mice (Figure 1A). This increase in body weight gain was not reduced by vehicle,
EMP, Alda-1 and EMP + Alda-1 treatments (Figure 1A). As expected, HFD-induced type-2
diabetes in ALDH2*2 mice increased hyperglycemia compared to chow-fed ALDH2*2
mice (Figure 1B). Among the treated groups, EMP and a combination of EMP and Alda-1
treatments decreased type-2 diabetes-mediated hyperglycemia compared to the vehicle
(Figure 1B). However, Alda-1 treatment did not reduce hyperglycemia (Figure 1B).
2.2. Effects of EMP, Alda-1 and EMP + Alda-1 on HFD-Induced Type-2 Diabetes Mediated
Glucose Intolerance
Similar to hyperglycemia, we found increased glucose intolerance in vehicle-treated
type-2 diabetic mice compared to chow-fed control mice (Figure 1C). EMP alone and as
well as in combination with Alda-1 significantly improved the glucose tolerance compared
to vehicle and Alda-1 (Figure 1C).
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2.4. Effects of EMP, Alda-1 and EMP + Alda-1 on Exercise Tolerance
We found that vehicle-treated ALDH2*2 mice with diabetes-associated HFpEF ran
shorter distances (Figure 3A) and duration (Figure 3B) until exhaustion compared to nondiabetic control ALDH2*2 mice. Treatment with EMP or Alda-1 and their combination
improved the running distance and duration in mice with diabetes-associated HFpEF
compared to vehicle treatment (Figure 3A,B). However, the combination of EMP + Alda-1
improved the running capacity of the mice with diabetes-associated HFpEF better than
EMP alone, as indicated by distance and duration (Figure 3A,B). The running distance is
positively correlated with % cardiac output (CO) (Figure 3C) and % EF (Figure 3D).
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2.5. Effects of EMP, Alda-1 and EMP + Alda-1 on ALDH2 Activity
We found that the myocardial ALDH2 activity was significantly reduced in vehicletreated ALDH2*2 mice with diabetes-associated HFpEF relative to non-diabetic control
mice (Figure 4). EMP, Alda-1 and EMP + Alda-1 treatments improved ALDH2 activity
significantly (Figure 4). However, the combination of EMP + Alda-1 potentiated the
activation of cardiac ALDH2 activity significantly compared to EMP or Alda-1 alone
(Figure 4). The increase in ALDH2 activity with EMP + Alda-1 treatment was much
higher compared to EMP, than Alda-1 (p < 0.05 vs. p < 0.01). However, in the individual
treatments, Alda-1 increased the ALDH2 activity and was more pronounced than EMP
(p < 0.01 vs. p < 0.001) (Figure 4).
2.6. Effects of EMP, Alda-1 and EMP + Alda-1 on 4HNE Protein Adducts
Cardiac levels of 4HNE protein adducts were higher in vehicle-treated ALDH2*2
diabetic mice with HFpEF relative to non-diabetic control mice (Figure 5A–C). These
increased cardiac 4HNE levels were attenuated by EMP or Alda-1 treatment (Figure 5A–C).
Finally, EMP + Alda-1 combination augmented the decrease in 4HNE protein adduct levels
compared to individual treatments with EMP or Alda-1 (Figure 5A–C).
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as shown in (B). * p < 0.05 refer to the difference between individual groups as shown in (C).

2.7. Effects of EMP, Alda‐1 and EMP + Alda‐1 on LKB1‐AMPK Signaling

We found a significant decrease in the LKB1 and phospho LKB1 (Ser428) levels with
vehicle treatment, which was increased with EMP or Alda‐1 (Figure 6A–D). However, this
LKB1 increase was further significantly augmented with EMP + Alda‐1 treatment (Figure
6A,B). The ratio of phospho LKB1 and LKB1 was significantly reduced in vehicle treat‐
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2.7. Effects of EMP, Alda-1 and EMP + Alda-1 on LKB1-AMPK Signaling
We found a significant decrease in the LKB1 and phospho LKB1 (Ser428) levels with
vehicle treatment, which was increased with EMP or Alda-1 (Figure 6A–D). However,
this LKB1 increase was further significantly augmented with EMP + Alda-1 treatment
(Figure 6A,B). The ratio of phospho LKB1 and LKB1 was significantly reduced in vehicle treatment compared to the controls (Figure 6A,D). Treatment with EMP, Alda-1 and
EMP + Alda-1 increased the ratio of phospho LKB1 and LKB1 (Figure 6A,D). We found a
significant decrease in AMPK levels with vehicle treatment compared to control (Figure 6E,F).
This decrease was not significantly changed with EMP, Alda-1 and EMP + Alda-1
(Figure 6E,F). The phospho AMPK (Thr 172) levels with vehicle treatment (Figure 6E,G)
Int. J. Mol. Sci. 2022, 23, x FOR PEER REVIEW
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was significantly reduced compared to controls mice. EMP or Alda-1 as well as a 8combination of EMP + Alda-1 increased phospho AMPK levels compared to vehicle treatment
(Figure 6E,G). In that, EMP + Alda-1 treatment augmented the increase in the phospho AMPK
levels
significantly
even when
to EMP
aloneintreatment
(Figure 6E,G).
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of
of
phospho
AMPK/AMPK
wascompared
significantly
reduced
vehicle treatment
compared
to the
phospho
AMPK/AMPK
was
significantly
reduced
in
vehicle
treatment
compared
to
the
controls (Figure 6E,H). The ratio of phospho AMPK/AMPK was significantly increased
controls
(Figure
The ratio
of phospho
AMPK/AMPK
was
significantly
increased
with
EMP,
Alda‐16E,H).
and EMP
+ Alda‐1
treatments
(Figure 6E,H).
EMP
+ Alda‐1 treatment
with EMP, Alda-1 and EMP + Alda-1 treatments (Figure 6E,H). EMP + Alda-1 treatment
mediated increase was significantly higher compared to EMP or Alda‐1 (Figure 6E,H).
mediated increase was significantly higher compared to EMP or Alda-1 (Figure 6E,H).
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2.8. Effects of EMP, Alda‐1 and EMP + Alda‐1 on 4HNE Adduction on LKB1
2.8. Effects of EMP, Alda-1 and EMP + Alda-1 on 4HNE Adduction on LKB1
We found a significant increase in colocalization of LKB1 and 4HNE in the hearts of
We found a significant increase in colocalization of LKB1 and 4HNE in the hearts
vehicle‐treated ALDH2*2 mice with diabetes‐associated HFpEF compared to the non‐di‐
of vehicle-treated ALDH2*2 mice with diabetes-associated HFpEF compared to the nonabetic
implicating
increased
4HNE adduction
on 7A,B,F,G,K,L,P,Q).
LKB1 (Figure
diabetic controls,
controls, implicating
increased
4HNE adduction
on LKB1 (Figure
7A,B,F,G,K,L,P,Q).
EMP
or
Alda‐1
significantly
decreased
4HNE
adduction
onvehicle
LKB1 com‐
EMP or Alda-1 significantly decreased 4HNE adduction on LKB1 compared to
treatpared
to
vehicle
treatment
(Figure
7C,D,H,I,M,N,P,Q).
The
combination
of
EMP
+ Alda‐1
ment (Figure 7C,D,H,I,M,N,P,Q). The combination of EMP + Alda-1 treatment decreased
treatment decreased 4HNE adduction on LKB1 compared to vehicle as well as EMP or
Alda‐1 (Figure 7B–Q). It appears that most of this colocalization occurs at the coronary
endothelial cells and some in blood cells in the blood vessels (Figure 7K–O).
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Figure 7. Co-immunostaining of LKB1 and 4HNE protein adducts in the cardiac sections. Representative micrographs of cardiac sections with immunostaining of LKB1 and 4HNE adducts and
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2.9. Effects of EMP, Alda‐1 and EMP + Alda‐1 on 8‐OHdG
2.9. Effects of EMP, Alda-1 and EMP + Alda-1 on 8-OHdG
We found a significant increase in myocardial 8‐OHdG, an index of oxidative DNA
We found
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8-OHdG, an index
of oxidative
DNA
damage,
in vehicle‐treated
mice
with diabetes‐associated
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to
damage,
in
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ALDH2*2
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with
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HFpEF
in
relation
control (Figure 8A,B,G). EMP or Alda‐1 significantly reduces myocardial 8‐OHdG (Figure
to controlEMP
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8A,B,G).
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than
EMP
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The
negative
control
in
Figure
8F
immunopositivity in Figure 8A–E.
explains the true immunopositivity in Figure 8A–E.
2.10. Effects of EMP, Alda-1 and EMP + Alda-1 on Cardiomyocyte Hypertrophy
We found a significant increase in cardiomyocyte hypertrophy in vehicle-treated
ALDH2*2 mice with HFpEF after type 2 DM in relation to control mice (Figure 9A,B,F). EMP
or Alda-1 significantly reduces cardiomyocyte hypertrophy (Figure 9A,D,F). EMP + Alda-1
induced a decrease in cardiomyocyte hypertrophy and was significantly higher than EMP
or Alda-1 (Figure 9A–F). This decrease by EMP + Alda-1 was significantly higher in EMP
(p < 0.01) than Alda-1 (p < 0.05).
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2.10. individual
Effects of EMP,
Alda‐1
and EMP + Alda‐1 on Cardiomyocyte Hypertrophy

We found a significant increase in cardiomyocyte hypertrophy in vehicle‐treated
ALDH2*2 mice with HFpEF after type 2 DM in relation to control mice (Figure 9A,B,F).
EMP or Alda‐1 significantly reduces cardiomyocyte hypertrophy (Figure 9A,D,F). EMP +
Alda‐1 induced a decrease in cardiomyocyte hypertrophy and was significantly higher
than EMP or Alda‐1 (Figure 9A–F). This decrease by EMP + Alda‐1 was significantly
higher in EMP (p < 0.01) than Alda‐1 (p < 0.05).
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We found a significant increase in myocardial fibrosis in vehicle‐treated ALDH2*2
mice with diabetes‐associated HFpEF in relation to control (Figure 10A,B,F). EMP or Alda‐
1 significantly reduces myocardial fibrosis (Figure 10A–D,F). EMP + Alda‐1 induced de‐
crease in myocardial fibrosis was significantly higher than EMP or Alda‐1 (Figure 10A–
E,F).
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2.11. Effects of EMP, Alda-1 and EMP + Alda-1 on Myocardial Fibrosis
We found a significant increase in myocardial fibrosis in vehicle-treated ALDH2*2
mice with diabetes-associated HFpEF in relation to control (Figure 10A,B,F). EMP or Alda-1
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significantly reduces myocardial fibrosis (Figure 10A–D,F). EMP + Alda-1 induced decrease
in myocardial fibrosis was significantly higher than EMP or Alda-1 (Figure 10A–E,F).
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eral studies have indicated that Asians develop diabetes at a younger age compared to
their Caucasian counterparts [17]. East Asians with the ALDH2*2 mutation have a higher
incidence of cardiovascular and metabolic diseases [18], such as diabetes [19], diabetes‐
induced neuropathy and vasculopathy [20] and diabetes‐induced diastolic dysfunction
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Several studies have indicated that Asians develop diabetes at a younger age compared to
their Caucasian counterparts [17]. East Asians with the ALDH2*2 mutation have a higher
incidence of cardiovascular and metabolic diseases [18], such as diabetes [19], diabetesinduced neuropathy and vasculopathy [20] and diabetes-induced diastolic dysfunction [21].
Our ALDH2*2 E487K knock-in mutant mice mimic East Asians with the ALDH2*2 E487K
mutation [22,23] and we demonstrated that this ALDH2*2 E487K knock-in mutant mice
with HFD-fed type-2 diabetes recapitulated major characteristics of HFpEF [6]. We found
increased diastolic dysfunction with preserved systolic function and poor exercise intolerance in these ALDH2*2 mice mimicking HFpEF features. The evidence to substantiate
this were decreased relaxation rate [the details of its calculation is provided in our previous
report [6]] along with preserved EF (>60%) and FS (>45%). In fact, in a recent clinical study,
the ALDH2*2 mutant variant is associated with an increased risk of HFpEF in patients
with hypertension, diabetes and coronary heart disease [14]. Most importantly, diabetes
was shown to decrease ALDH2 activity in non-ALDH2*2 mutant animals i.e., WT animals
as well [24]. Thus, our research findings will be applicable to all patients with metabolic
stress, more so for East Asians with the ALDH2*2 mutation. We have recently shown that
ALDH2*2 mutant diabetic hearts have reduced coronary endothelial density and Alda-1
can reduce the coronary endothelial cell damage in the myocardium [25], since HFpEF
originates from systemic oxidative stress, inflammation, and endothelial cell dysfunction at
the cardiac tissue levels. We presume Alda-1 prevented 4HNE-mediated inflammation and
thereby ameliorated HFpEF in the current model. To specifically understand the role of
4HNE in the coronary endothelial cell damage, we employed mouse coronary endothelial
cells in our recent studies [11,12]. In fact, this study also displays that increased 4HNE
adduction in LKB1 was higher in coronary endothelial cells (Figure 7).
Similar to Alda-1, EMP alone improved cardiac function and exercise tolerance in
the mice with HFpEF by decreasing hyperglycemia-mediated 4HNE adducts. Notably,
EMP is gaining importance in T2DM patients as its benefits extend beyond its glucoselowering action [26–28]. Specifically, its effect, which led to improvements in heart failure
patients and cardiovascular death, is striking in the landmark randomized clinical trial
(RCT) EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type
2 Diabetes Mellitus Patients) [29]. A meta-analysis of RCTs has also confirmed the benefits
of EMP [30]. Gupte et al. [26] summarized clinical, preclinical and meta-analysis of SGLT2
inhibitors mediated cardiac benefits. Ongoing RCTs are planned to study the effects of
EMP in HFpEF [31,32]. For instance, SUGAR-DM-HF (Studies of Empagliflozin and Its
Cardiovascular, Renal and Metabolic Effects) RCT will check for the effects of empagliflozin
on specific pathways in cardiac and renal effects in patients with type 2 diabetes (or prediabetes) and HF. In a study using explanted cardiac papillary muscle from murine (diabetic
and non-diabetic) and human HF subjects, EMP directly reduced diastolic dysfunction via
improving myofilament function with enhanced myofilament phosphorylation [33].
As roughly 130 million diabetics live in the Western Pacific region, with a significant
proportion in East Asia including China, Philippines, Japan and Korea [17], a sub analysis
of EMP treatment in the Asian population within EMPA-REG OUTCOME was performed;
it revealed that EMP was beneficial to Asians as well [34], which underscores our interest
to focus on the ALDH2*2 mutation and increases the propensity to develop diabetic cardiac
dysfunction [21] as well as HFpEF in East Asians [14]. There are few diabetic animal studies
where the beneficial cardiovascular effects of EMP were shown [26,35,36], including our
previous study in which EMP was shown to improve cardiac function and exercise tolerance
in the same animal model by diminishing hyperglycemia-mediated 4HNE adducts [15].
The highlight of this study is the evaluation of the EMP + Alda-1 combination mediated pharmacological effects on diabetes-associated HFpEF. The addition of Alda-1 to
EMP improved cardiac diastolic dysfunction before exercise stress. After the exercise stress,
the combination treatment showed improvements in both diastolic and systolic function
besides increasing heart rate. At the cell signaling level, the combination treatment was
better in increasing ALDH2 activity, reducing 4HNE protein adducts level and improving
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the LKB1-AMPK signaling pathway, i.e., the increase in the Ser428 pLKB1 and Thr172
pAMPK, and decreasing 4HNE adduction on LKB1. Earlier studies implicated that cardiacspecific haplodeficiency of LKB1 in mice fed with HFD and a high-sucrose diet causes
deleterious effects at multiple levels [37], including: (1) cardiac functional level—diastolic
dysfunction and systolic failure; (2) cellular level—apoptosis, hypertrophy and fibrosis;
(3) organelle level—mitochondrial dysfunction as well as (4) signaling level—decrease in
AMPK phosphorylation. Pertaining to our line of thinking, 4HNE adduction on essential
signaling proteins afflicts cardiac tissue and causes abnormal function [37]. For instance, in
spontaneously hypertensive rats, 4HNE adduction on LKB1 in hypertrophic myocardium
was shown in reducing AMPK phosphorylation [38]. In that report, 4HNE-mediated inhibition of the LKB1/AMPK signaling was established as critical signaling in the hypertrophic
process [38]. Furthermore, at the molecular level, modification at Lys-97 by 4HNE alone can
inhibit LKB1 [39]. Even though we did not perform such molecular studies in our current
study, our interpretation of the results suggest that decreasing 4HNE protein adduct levels
by two different pharmacological approaches protects LKB1 from 4HNE adduction and
thus improving its activity as evident from increased phosphorylation of LKB1 at Ser428
and then its substrate, AMPK at Thr172. Therefore, we propose that efficient removal of
cardiac tissue at the 4HNE level by both augmenting ALDH2 activation mediated 4HNE
detoxification, along with decreasing hyperglycemia-mediated 4HNE production, will be
beneficial in ameliorating diabetes-associated HFpEF, which can be tested in other HFpEF
models where oxidative stress ensues. Subcutaneously injected Elamipretide (MTP-131), a
novel mitochondria-targeting peptide, into heart failure dogs for 3 months significantly
decreased cardiac 4HNE, increased LV ejection fraction and improved mitochondrial respiration in treated dogs [40]. Even though it may be just concurrence however, further
studies on large animals such as dogs and pigs will solidify that decreasing 4HNE will
be beneficial in ameliorating HFpEF. In a type-1 diabetic model we have also shown that
decreasing 4HNE adduction reduced cardiac damage [5].
In conclusion, 4HNE-protein adduction-mediated cell signaling aberrations are critical
in HFpEF. Thus, targeting 4HNE removal from the organ systems can serve as a key strategy
to alleviate HFpEF.
4. Materials and Methods
4.1. High-Fat Diet (HFD)-Fed Type-2 Diabetes Mellitus in ALDH2*2 Mutant Heterozygous Mice
ALDH2*2 knock-in mutant male heterozygous mice (with C57BL/6J background) with
3–4 months of age were fed an HFD (60% of calories from fat, D12492, Research Diets) as we
published earlier [6]. Normal chow-fed ALDH2*2 mice were served as controls. In the HFDfed group, the mice with sustained elevated fasting blood glucose levels above 250 mg/dL
were deemed as diabetic mice and selected for further treatments. ALDH2*2 mice were
inbred in-house and genotyped by Transnetyx Inc., Cordova, TN, USA. The animal protocol
was approved by the Henry Ford Health System and Wayne State University Institutional
Animal Care and Use Committee. We confirm that all experiments were performed in
accordance with IACUC guidelines and regulations. All the animal experiments followed
the ethical guidelines of ARRIVE.
4.2. Intraperitoneal Glucose Tolerance Test (IPGTT)
The IPGTT was performed in ALDH2*2 knock-in mutant male heterozygous mice
from control and diabetic groups as explained elsewhere [4]. After fasting for 6 h, the mice
were injected with 2 g/kg D-glucose. Then, blood glucose levels were measured at 0, 30, 60,
90 and 120 min after D-glucose injection, using a glucometer.
4.3. Pharmacological Treatment Protocols
At the end of 6 months, we divided the diabetic ALDH2*2 heterozygous mice randomly into 4 groups with n = 8 animals for each group: DMSO as vehicle (Veh); an
SGLT2 inhibitor, EMP (3 mg/kg/d) to reduce hyperglycemia; an ALDH2 activator, Alda-1
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(10 mg/kg/d) to enhance ALDH2 activity (Alda-1); as well as a combination of EMP + Alda-1.
These agents were administered via using Alzet Mini-osmotic pumps (Model # 2004; 0.25 µL
per hour, 28 days) by implanting subcutaneously (we changed the pumps after 28 days for
one more time to administer for 56 days (i.e., 8 weeks). We selected the dose of EMP from
previously published studies from us [15] and others [41–43]. Similarly, Alda-1 dose was
selected from previous studies [44–46]. After 8 weeks of treatments, cardiac function was
assessed by conscious echocardiography post-exercise stress.
4.4. Cardiac Function Assessment by Echocardiography in Conscious Mice
To avoid the effects of anesthesia, we assessed left ventricular dimension and function
in conscious mice using an echocardiograph equipped with a 15-MHz linear transducer
(Acuson c256, Malvern, PA, USA) as we described previously [4,6,47].
4.5. Acute Progressive Maximal Exercise Test (Exhaustion Test)
The non-diabetic control ALDH2*2 mice and diabetic ALDH2*2 mice treated with
vehicle, EMP, Alda-1 and EMP + Alda-1 combination were subjected to the exercise exhaustion test as described earlier [6]. We calculated running distance of the mice from
the recording.
4.6. Post-Exercise Echocardiography
Immediately after finishing the exercise exhaustion test, we performed conscious
echocardiography again on the mice to record their functional changes. We calculated heart
rate, fractional shortening (% FS) and % ejection fraction (% EF) for systolic functional
parameters and, relaxation rate (RR) and left atrial (LA) area for diastolic dysfunction.
4.7. Histopathology
The middle portions of the cardiac tissue were fixed with 10% formalin in PBS, embedded in paraffin as blocks, and several transverse sections were cut for histopathological studies.
4.8. Measurement of Cardiomyocyte Hypertrophy
The myocardial sections were stained with hematoxylin-eosin (H-E). H-E-stained
cardiac sections were used to measure cardiomyocyte diameter to determine hypertrophy
as we reported earlier [4,5]. We randomly picked 4 samples from each group to measure
cardiomyocyte diameter.
4.9. Measurement of Cardiac Fibrosis
The myocardial sections were stained with Mason’s Trichrome. The red color indicates
the deposition of collagen and this area was measured using the MicroSuite Basic software
(Olympus America, Center Valley, PA, USA). The percent (%) area of fibrosis was quantified
from each tissue section as previously described [5,25]. We randomly picked 4 samples
from each group to measure cardiac fibrosis.
4.10. ALDH2 Activity Assay
The cardiac ALDH2 activity was measured as we described in previous reports [4,12].
In brief, the protein samples were allowed to react with 50 mM sodium pyrophosphate
as a buffer, 2.5 mM NAD+ as a cofactor and 10 mM acetaldehyde as substrate. The
reductive reaction of NAD+ to NADH at λ340 nm wavelength at 37 ◦ C temperature was
measured as ALDH2 activity. We randomly picked 4 samples from each group to measure
ALDH2 activity.
4.11. Western Immunoblotting
The Western blot was performed as described earlier (6, 13). In brief, protein samples
from cardiac tissue were separated on SDS-polyacrylamide gels by electrophoresis and
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transferred to immobilon-P membranes (Millipore, Billerica, MA, USA). The changes in
the protein levels in cardiac tissue samples were determined using antibodies of anti4HNE-Cys/His/Lys rabbit antibody (Millipore, Billerica, MA, USA), anti-liver kinase B1
(LKB1) antibody (Cell Signaling Technology, Danvers, MA, USA), anti-phospho LKB1
(Ser428) antibody (Cell Signaling Technology, Danvers, MA, USA), AMP-activated protein
kinase (AMPK) and anti-phospho AMP-activated protein kinase (Thr 172) antibody (Cell
Signaling Technology), along with anti-GAPDH antibody (Santacruz) that was used as a
housekeeping marker and loading control. The horseradish peroxidase (HRP)-coupled
respective secondary antibodies were added to form complexes with primary antibodies
which were then visualized by using chemiluminescence detection reagents. We randomly
picked 4 samples from each group to do Western immunoblotting.
4.12. Immunohistochemistry Staining of 8-Hydroxy-20 -Deoxyguanosine (8OHdG)
Formalin-fixed, paraffin-embedded cardiac biventricular tissue sections were used
for immunohistochemical staining. After deparaffinization and hydration, the slides were
washed in Tris-buffered saline (TBS; 10 mmol/L Tris–HCl, 0.85% NaCl, pH 7.5) containing
0.1% bovine serum albumin (BSA). Endogenous peroxidase activity was quenched by
incubating the slides in 0.6% H2 O2 /methanol. A pressure cooker method was used to
retrieve the antigen. In the following steps, reagents from an immunoperoxidase staining
kit (Millipore, Billerica, MA, USA) were used as directed. A solution from the kit was
used to block non-specific reactions. After overnight incubation with mouse 8OHdG
antibody (Abcam, Cambridge, MA, USA) at a concentration of 1:200 and 4 ◦ C, the slides
were washed in TBS. Secondary antibody solution and streptavidin peroxidase solution
were added and incubated at room temperature. Immunostaining was visualized with
chromogen, diaminobenzidine tetrahydrochloride (DAB). After overnight incubation with
mouse 8OHdG antibody (Abcam, Cambridge, MA, USA) at a concentration of 1:200 at 4 ◦ C,
the slides were washed in TBS. We counted the brown color spots as 8OHdG positivity in
the cardiac sections from various groups using light microscope (Olympus America, Center
Valley, PA, USA) and plotted them as a graph as we reported earlier [24,25]. We randomly
picked 4 samples from each group to perform immunostaining of 8OHdG.
4.13. Immunofluorescence Staining of LKB1 and 4HNE Adducts
Formalin-fixed, paraffin-embedded cardiac biventricular tissue sections were used for
immunostaining as we explained elsewhere [24]. After deparaffinization and hydration,
the slides were washed in Tris-buffered saline (TBS; 10 mmol/L Tris–HCl, 0.85% NaCl,
pH 7.5) containing 0.1% bovine serum albumin (BSA). A pressure cooker method was
used to retrieve the antigen. In the following steps, reagents from an immunoperoxidase
staining kit (Millipore) were used as directed. A solution from the kit was used to block
non-specific reactions. The following antibodies were used for co-immunostaining at a
concentration of 1:100 and 4 ◦ C for overnight incubation: anti-LKB1 mouse monoclonal
antibody (Thermofischer Scientific Inc., Waltham, MA, USA) and anti-4HNE-Cys/His/Lys
rabbit polyclonal antibody (Millipore Sigma, Burlington, MA, USA). The secondary antibodies were conjugated with FITC and rhodamine (Thermofischer Scientific Inc. Waltham,
MA, USA) at a concentration of 1:500 at room temperature for 1 h. Immunofluorescence
positive staining was analyzed using an Olympus microscope and an image analyzer. We
randomly picked 4 samples from each group to perform co-immunostaining of LKB1 and
4HNE protein adducts.
4.14. Statistical Analysis
Data are presented as mean ± standard error of the mean (S.E.M). We used One-Way
ANOVA for group comparisons and the post-hoc analysis was performed using Student
t-test. The differences between before and after exercise stress with individual groups
were analyzed by using the paired Student t-test. We used Microsoft Excel 2013 for all
statistical analysis.
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5. Perspectives
This study shows that combined treatment with EMP, a SGLT2 inhibitor that lowers
hyperglycemia and Alda-1, an ALDH2 activator, improved exercise tolerance and diastolic
function better than EMP alone in a mouse model of HFpEF associated with diabetes. This
was mediated by reduced cardiac 4HNE protein adduct levels due to decreased 4HNE
production via EMP and augmented 4HNE detoxification by Alda-1.
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